Vanta Bioscience

Vanta Bioscience

24.85
-1.30
(-4.97%)
Market Cap
16.50 Cr
EPS
-7.56
PE Ratio
-
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
64.84
52 Week Low
19.08
PB Ratio
1.58
Debt to Equity
3.61
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
657.60
#1 26,497.30
51.59
#1 3,714.20
3.77
#1 496
14.53
41.91
572.60
13,746.30
#1 31.66
2,946.50
10.53
407
32.73
53.48
239.00
5,211.96
-
17.60
#1 49.09
-161
-65.66
34.07
644.05
2,866.38
44.60
322.30
0.22
41
112.87
54.25
67.60
159.16
-
788.04
-22.39
-71
#1 133.33
41.99
9.36
138.47
50.61
0.00
-65.97
37
76.32
39.51
42.48
67.29
493.63
46.84
8.04
0
-85.71
57.57
18.00
26.30
33.09
83.71
-3.26
2
-94.64
46.55
24.85
#9 16.50
-
#8 1.96
#2 40.00
#7 -13
#9 -566.67
46.96
Forecast
Actual
Growth Rate
Revenue Growth
40.00 %
Net Income Growth
-17.31 %
Cash Flow Change
525.40 %
ROE
20.22 %
ROCE
-24.77 %
EBITDA Margin (Avg.)
-158.91 %

Quarterly Financial Results

Quarterly Financials
Dec 2021
Mar 2022
Dec 2022
Mar 2023
Revenue
0
5
3
1
Expenses
0
2
3
2
EBITDA
0
2
-1
-1
Operating Profit %
0 %
46 %
-20 %
-206 %
Depreciation
0
1
1
0
Interest
0
1
3
1
Profit Before Tax
0
1
-4
-2
Tax
0
0
-2
-0
Net Profit
0
0
-3
-1
EPS in ₹
0.00
0.11
-4.06
0.00

Balance Sheet

Balance Sheet
2019
2020
2021
2022
2023
2024
2025
Total Assets
39
49
70
81
85
85
86
Fixed Assets
18
21
29
36
57
54
69
Current Assets
17
20
20
15
15
17
15
Capital Work in Progress
4
7
19
29
11
13
0
Investments
2
0
0
0
0
0
7
Other Assets
16
21
21
17
17
19
0
Total Liabilities
39
49
70
81
85
85
86
Current Liabilities
3
10
15
18
18
23
27
Non Current Liabilities
13
14
29
34
48
50
56
Total Equity
23
25
26
29
19
13
10
Reserve & Surplus
16
17
18
18
11
9
4
Share Capital
6
6
6
6
6
6
6

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
Net Cash Flow
3
-3
3
-2
-0
0
Investing Activities
-6
-8
-22
-17
-6
-3
Operating Activities
-1
2
7
5
-1
3
Financing Activities
10
2
18
10
6
1

Share Holding

% Holding
Mar 2021
Sept 2021
Mar 2022
Sept 2022
Mar 2023
Sept 2023
Mar 2024
Sept 2024
Mar 2025
Promoter
69.11 %
69.00 %
69.00 %
69.36 %
69.36 %
69.36 %
69.36 %
69.36 %
69.36 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
26.39 %
26.41 %
26.35 %
26.56 %
26.77 %
26.77 %
25.97 %
26.55 %
26.35 %
Others
4.50 %
4.59 %
4.65 %
4.08 %
3.87 %
3.87 %
4.67 %
4.09 %
4.29 %
No of Share Holders
361
412
409
393
394
388
418
424
408

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
01 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
01 Aug 2025 23.85 28.29
04 Jan 2025 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
04 Jan 2025 43.50 42.21
14 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Nov 2024 48.02 43.34
30 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Sept 2024 46.70 50.99

Announcements

Financials For The Half Year And Year Ended 31.03.2025Aug 01, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held On 01.08.2025Aug 01, 2025
Board Meeting Intimation for Postponement Of Board Meeting To August 01 2025Jul 29, 2025
Board Meeting Intimation for Postponement Of Board Meeting To July 29 2025Jul 26, 2025
Board Meeting Intimation for Postponement Of Board Meeting Scheduled On July 19 2025 And Will Now Be Held On Thursday July 24 2025Jul 19, 2025
Board Meeting Intimation for Board Meeting To Be Held On July 19 2025Jul 16, 2025
Rejection Of Promoter Reclassification ApplicationJun 16, 2025
Cancellation of Board MeetingMay 29, 2025
Results-Delay in Financial ResultsMay 29, 2025
Board Meeting Intimation for Board Meeting On 30/05/2025May 21, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011May 09, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On 06.05.2025May 06, 2025
Intimation Regarding Receipt Of GLP Re-Certification For The Facility Of The Company In Gummidipundi Tamil NaduMay 02, 2025
Closure of Trading WindowMar 29, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJan 07, 2025
Notice Of EGM To Be Held On 04.01.2025Dec 12, 2024
EGM On 04.01.2025Dec 07, 2024
Board Meeting Outcome for Outcome Of Board Meeting Held On 06.12.2024Dec 06, 2024
Board Meeting Intimation for Conversion Of Unsecured Loans Into Equity SharesDec 03, 2024
Unaudited Results For 30.09.2024Nov 14, 2024
Board Meeting Outcome for Outcome Of Board Meeting Held On 14.11.2024Nov 14, 2024
Board Meeting Intimation for Approval Of Un-Audited Financial Statements Of 30.09.2024 And Conversion Of Unsecured Loans Into Equity SharesNov 11, 2024
Reply To Clarification On Price Movement Sought By BSENov 07, 2024
Clarification sought from Vanta Bioscience LtdNov 06, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportOct 01, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2024
Closure of Trading WindowSep 28, 2024
Submission Of Revised Financial Statements For The Period Ended 31.03.2024 Pursuant To Query From BSE Regarding Bifurcation Of Trade PayablesSep 19, 2024
Reg. 34 (1) Annual Report.Sep 06, 2024
AGM On 30.09.2024Sep 06, 2024
Board Meeting Outcome for Outcome Of Board Meeting Held On 06.09.2024 - 8Th Annual General Meeting To Be Held On 30.09.2024Sep 06, 2024
Intimation Of Submission Of Application To BSE For Reclassification From 'Promoter' Category To 'Public' CategoryAug 18, 2024
Regulation 30 - Submission Of Resignation Letters Of Directors Dated 19.07.2024Jul 24, 2024
Approval Of Board For Reclassification Of 2 Promoters To Public CategoryJul 20, 2024
Approval Of Board For Reclassification Of 2 Promoters To Public CategoryJul 20, 2024
Results For The Period Ended 31.03.2024Jul 19, 2024
Board Meeting Outcome for Outcome Of Board Meeting Held On 19.07.2024Jul 19, 2024
Board Meeting Intimation for Intimation Regarding Postponement Of Board Meeting To 19.07.2024 For Approval Of Financial Results Of The CompanyJul 17, 2024
Board Meeting Intimation for Approval Of Financial Results For The Half Year And Year Ended 31.03.2024Jul 10, 2024
Compliance Certificate Under Regulation 40(9)Apr 21, 2024
Reg. 34 (1) Annual Report.Apr 21, 2024
Compliance Certificate Under Regulation 7(3)Apr 21, 2024
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderApr 02, 2024
Appointment of Company Secretary and Compliance OfficerApr 01, 2024
Closure of Trading WindowMar 30, 2024
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderDec 01, 2023
Change In Designation Of Dr. Vyasmurti Madhavrao Shingatgeri (DIN 07728757) From Whole Time Director To Non-Executive Director W.E.F 14.11.2023.Nov 14, 2023
Board Meeting Outcome for Outcome Of Board Meeting Held On 14.11.2023Nov 14, 2023
Board Meeting Intimation for Approval Of Unaudited Financial Statements For The Period Ended 30.09.2023Nov 08, 2023
Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP)Nov 02, 2023

Technical Indicators

RSI(14)
Neutral
46.96
ATR(14)
Less Volatile
1.15
STOCH(9,6)
Oversold
9.03
STOCH RSI(14)
Oversold
9.07
MACD(12,26)
Bearish
-0.56
ADX(14)
Weak Trend
22.26
UO(9)
Bearish
31.88
ROC(12)
Downtrend And Accelerating
-9.80
WillR(14)
Oversold
-81.83